In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints

Papaparaskevas, Joseph; Tzouvelekis, L. S.; Tsakris, Athanassios; Pittaras, Theodore; Nj, Legakis

doi:10.1016/j.diagmicrobio.2009.09.012

Cited by 16 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that the tigecycline susceptibility rates for ESBL-producing K. pneumoniae measured using FDA criteria were about 10% higher than those measured using EUCAST breakpoints. Similar differences in susceptibility rates obtained using the two criteria were noted in a study conducted in Greece, namely, that the susceptibility rates for K. pneumoniae were 99% according to FDA criteria and 91% as measured using EUCAST criteria (16). That study also reported a major difference in susceptibility of isolates of Enterobacter spp.…”

Section: Resultssupporting

confidence: 66%

“…That study also reported a major difference in susceptibility of isolates of Enterobacter spp. (16). In a study conducted during the period from 2005 to 2009 in the United States, the rates of tigecycline susceptibility as measured by FDA and EUCAST criteria differed by 0.6% for ESBL-producing E. coli (100% versus 99.4%; n ϭ 334; P ϭ 0.499) and by 7.3% for K. pneumoniae (97.9% versus 90.6%; n ϭ 426; P Ͻ 0.001) (18).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Trends in the Susceptibility of Clinically Important Resistant Bacteria to Tigecycline: Results from the Tigecycline In Vitro Surveillance in Taiwan Study, 2006 to 2010

Chen

Huang

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The TigecyclineIn VitroSurveillance in Taiwan (TIST) study, a nationwide, prospective surveillance during 2006 to 2010, collected a total of 7,793 clinical isolates, including methicillin-resistantStaphylococcus aureus(MRSA) (n= 1,834), penicillin-resistantStreptococcus pneumoniae(PRSP) (n= 423), vancomycin-resistant enterococci (VRE) (n= 219), extended-spectrum β-lactamase (ESBL)-producingEscherichia coli(n= 1,141), ESBL-producingKlebsiella pneumoniae(n= 1,330),Acinetobacter baumannii(n= 1,645), andStenotrophomonas maltophilia(n= 903), from different specimens from 20 different hospitals in Taiwan. MICs of tigecycline were determined following the criteria of the U.S. Food and Drug Administration (FDA) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST-2011). Among drug-resistant Gram-positive pathogens, all of the PRSP isolates were susceptible to tigecycline (MIC90, 0.03 μg/ml), and only one MRSA isolate (MIC90, 0.5 μg/ml) and three VRE isolates (MIC90, 0.125 μg/ml) were nonsusceptible to tigecycline. Among the Gram-negative bacteria, the tigecycline susceptibility rates were 99.65% for ESBL-producingE. coli(MIC90, 0.5 μg/ml) and 96.32% for ESBL-producingK. pneumoniae(MIC90, 2 μg/ml) when interpreted by FDA criteria but were 98.7% and 85.8%, respectively, when interpreted by EUCAST-2011 criteria. The susceptibility rate forA. baumannii(MIC90, 4 μg/ml) decreased from 80.9% in 2006 to 55.3% in 2009 but increased to 73.4% in 2010. A bimodal MIC distribution was found among carbapenem-susceptibleA. baumanniiisolates, and a unimodal MIC distribution was found among carbapenem-nonsusceptibleA. baumanniiisolates. In Taiwan, tigecycline continues to have excellentin vitroactivity against several major clinically important drug-resistant bacteria, with the exception ofA. baumannii.

show abstract

Section: Resultssupporting

confidence: 66%

Section: Resultsmentioning

confidence: 99%

Trends in the Susceptibility of Clinically Important Resistant Bacteria to Tigecycline: Results from the Tigecycline In Vitro Surveillance in Taiwan Study, 2006 to 2010

Chen

Huang

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Although tigecycline has not been approved for hospital-acquired pneumonia, some studies report excellent tissue penetration in murine epithelial lung fluid of tigecycline 24 and its efficacy in Acinetobacter sp. 3,22 Moreover, decreased activity of tigecycline against A baumannii, as was found in this study and was reported in a previous study, 17 should be considered for patients with persistent A baumannii infection because we noted A baumannii, secondary to P aeruginosa, as one of the important superinfection pathogens during tigecycline treatment. To avoid the selection of tigecycline-resistant A baumannii, some authorities suggest a higher mutant prevention concentration in the treatment of carbapenem-resistant A baumannii.…”

Section: Discussionsupporting

confidence: 49%

“…22 The impact of tigecycline on gut colonization was not assessed in this study. Our results revealed that tigecycline did not increase infections with clinical Candida species.…”

Section: Discussionmentioning

confidence: 98%

“…Tigecycline was reported to have similar MIC 50 and MIC 90 in both imipenemsensitive and imipenem-resistant Acinetobacter sp. 22 Because 57% of A baumannii causing nosocomial infections in 13 Taiwan intensive care units were resistant to carbapenem, 23 tigecycline, colistin, or sulbactam is still considered as an important treatment option. Although tigecycline has not been approved for hospital-acquired pneumonia, some studies report excellent tissue penetration in murine epithelial lung fluid of tigecycline 24 and its efficacy in Acinetobacter sp.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Microbial isolation and emergence of antimicrobial resistance associated with tigecycline usage

Chen

et al. 2011

Journal of Microbiology, Immunology and Infection

View full text Add to dashboard Cite

show abstract

In Vitro Activity of Tigecycline Against Acinetobacter baumannii: Global Epidemiology and Resistance Mechanisms

Pournaras

Koumaki

Gennimata

et al. 2015

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Acinetobacter baumannii is a pathogen of increasing concern, commonly causing outbreaks in the hospital environment. Of particular concern, A. baumannii strains exhibiting resistance to carbapenems, which were previously considered the treatment of choice for infected patients, have dramatically increased worldwide, leaving a few antibacterial choices. Tigecycline, a broad-spectrum modified minocycline derivative, isconsidered as a last resort drug against multidrug-resistant A. baumannii. Though, resistance to tigecycline has emerged and is growing notably following increasing tigecycline usage. Comparative evaluation of the tigecycline resistance rates reported worldwide is challenging due to the absence of official interpretative criteria for in vitro susceptibility testing and the discrepancies among the different susceptibility methodologies used, with broth microdilution being considered the reference method. Tigecycline resistance is mainly associated with resistance-nodulation-cell division (RND)-type transporters, mainly the AdeABC, AdeFGH and AdeIJK efflux pumps, but other resistance mechanisms have also been implicated. Tigecycline is still an attractive choice for A. baumannii, but further investigations are warranted so that treatment of MDR Α. baumannii could be guided by validated in vitro data.

show abstract

In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints

Cited by 16 publications

References 16 publications

Trends in the Susceptibility of Clinically Important Resistant Bacteria to Tigecycline: Results from the Tigecycline In Vitro Surveillance in Taiwan Study, 2006 to 2010

Trends in the Susceptibility of Clinically Important Resistant Bacteria to Tigecycline: Results from the Tigecycline In Vitro Surveillance in Taiwan Study, 2006 to 2010

Microbial isolation and emergence of antimicrobial resistance associated with tigecycline usage

In Vitro Activity of Tigecycline Against Acinetobacter baumannii: Global Epidemiology and Resistance Mechanisms

Contact Info

Product

Resources

About